Suppr超能文献

疫苗的作用以及为实现公共卫生大融合目标而进行的疫苗决策。

The role of vaccines and vaccine decision-making to achieve the goals of the Grand Convergence in public health.

作者信息

Kaslow David C, Kalil Jorge, Bloom David, Breghi Gianluca, Colucci Anna Maria, De Gregorio Ennio, Madhavan Guru, Meier Genevieve, Seabrook Richard, Xu Xiaoning

机构信息

PATH, Seattle, WA, USA.

Instituto Butantan, Brazil.

出版信息

Vaccine. 2017 Jan 20;35 Suppl 1:A10-A15. doi: 10.1016/j.vaccine.2016.10.088. Epub 2016 Dec 22.

Abstract

On 17 and 18 July 2015, a meeting in Siena jointly sponsored by ADITEC and GlaxoSmithKline (GSK) was held to review the goals of the Global Health 2035 Grand Convergence, to discuss current vaccine evaluation methods, and to determine the feasibility of reaching consensus on an assessment framework for comprehensively and accurately capturing the full benefits of vaccines. Through lectures and workshops, participants reached a consensus that Multi-Criteria-Decision-Analysis is a method suited to systematically account for the many variables needed to evaluate the broad benefits of vaccination, which include not only health system savings, but also societal benefits, including benefits to the family and increased productivity. Participants also agreed on a set of "core values" to be used in future assessments of vaccines for development and introduction. These values include measures of vaccine efficacy and safety, incident cases prevented per year, the results of cost-benefit analyses, preventable mortality, and the severity of the target disease. Agreement on this set of core assessment parameters has the potential to increase alignment between manufacturers, public health agencies, non-governmental organizations (NGOs), and policy makers (see Global Health 2035 Mission Grand Convergence [1]). The following sections capture the deliberations of a workshop (Working Group 4) chartered to: (1) review the list of 24 parameters selected from SMART vaccines (see the companion papers by Timmis et al. and Madhavan et al., respectively) to determine which represent factors (see Table 1) that should be taken into account when evaluating the role of vaccines in maximizing the success of the Global Health 2035 Grand Convergence; (2) develop 3-5 "core values" that should be taken into account when evaluating vaccines at various stages of development; and (3) determine how vaccines can best contribute to the Global Health 2035 Grand Convergence effort.

摘要

2015年7月17日至18日,由ADITEC和葛兰素史克公司(GSK)联合主办的一场会议在锡耶纳召开,旨在审视《全球健康2035大融合》的目标,讨论当前的疫苗评估方法,并确定就一个全面、准确衡量疫苗全部益处的评估框架达成共识的可行性。通过讲座和研讨会,与会者达成共识,即多标准决策分析是一种适合系统考量评估疫苗广泛益处所需诸多变量的方法,这些变量不仅包括卫生系统节省的成本,还包括社会效益,如对家庭的益处和生产力提高。与会者还就一套“核心价值”达成一致,这些核心价值将用于未来对疫苗研发和引入的评估。这些价值包括疫苗效力和安全性指标、每年预防的发病病例数、成本效益分析结果、可预防死亡率以及目标疾病的严重程度。就这组核心评估参数达成一致,有可能增进制造商、公共卫生机构、非政府组织(NGO)和政策制定者之间的协同(见《全球健康2035使命大融合》[1])。以下各节记录了一个专门研讨会(第4工作组)的审议情况,该研讨会旨在:(1)审视从SMART疫苗中选出的24个参数列表(分别见Timmis等人和Madhavan等人的配套论文),以确定哪些参数代表在评估疫苗在实现《全球健康2035大融合》成功方面的作用时应考虑的因素(见表1);(2)制定在评估疫苗研发各个阶段时应考虑的3至5个“核心价值”;(3)确定疫苗如何能最佳地推动《全球健康2035大融合》的努力。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验